Kingworld Medicines Group Ltd. Reports 23% Decline in Revenue and 74.9% Drop in Profit for H1 2025; EPS Falls from 5.20 to -0.94 RMB Cents

Kingworld Medicines Group Ltd. has released its interim financial results for the six months ended June 30, 2025. During this period, the company reported a revenue of RMB 404.85 million, reflecting a decrease of 23% from the RMB 526.088 million recorded in the same period of 2024. The cost of sales decreased by 22.1% to RMB 302.807 million, down from RMB 388.828 million in the previous year. The gross profit for the period was RMB 102.043 million, representing a decline of 25.7% from RMB 137.26 million in 2024. The gross profit margin experienced a slight reduction, moving from 26.1% to 25.2%, a decrease of 0.9 percentage points. Net profit for the period was RMB 11.436 million, a significant drop of 74.9% compared to RMB 45.62 million in the corresponding period of the previous year. Loss attributable to owners of the company was RMB 5.412 million, compared to a profit of RMB 30.716 million in 2024. Looking forward, Kingworld Medicines Group Ltd. aims to strengthen its position in the market by continuing to deepen nationwide marketing collaborations with upstream suppliers, as part of its strategic initiatives under the Group’s Fifth Five-Year Plan. This effort is intended to provide momentum for the company’s development in the second half of 2025. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kingworld Medicines Group Ltd. published the original content used to generate this news brief on September 18, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here